Item 8.01 Other Events.
On March 17, 2026, CytomX Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering, issuance and sale by the Company of 45,990,567 shares of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), at an offering price of $5.30 per share, and pre-funded warrants to purchase 1,179,245 shares of Common Stock (the “Pre-Funded Warrants”) at a price of $5.29999 per Pre-Funded Warrant.
In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters the option, for 30 days, to purchase up to 7,075,471 additional shares of Common Stock at the public offering price.
The offering was made pursuant to a registration statement on Form S-3 (Registration No. 333-294342) filed on March 16, 2026, including a base prospectus contained therein, and a prospectus supplement dated March 17, 2026. On March 19, 2026, the offering closed and the Company completed the sale and issuance of an aggregate of 45,990,567 shares of Common Stock and Pre-Funded Warrants to purchase 1,179,245 shares of Common Stock.
The Company estimates the net proceeds from the offering will be approximately $234.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering for the continued development of Varseta-M and other pipeline programs, as well as general corporate purposes and working capital needs.
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.
The foregoing descriptions of the Underwriting Agreement and the Pre-Funded Warrants are not complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement and form of Pre-Funded Warrant, copies of which are filed as Exhibits 1.1 and 4.1 to this Current Report on Form 8-K, respectively, and are incorporated by reference herein.
Latham & Watkins LLP, counsel to the Company, has issued an opinion regarding the validity of the foregoing securities offered and sold in the offering, a copy of which is filed a Exhibit 5.1 hereto.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
| Exhibit No. |
|
Description |
|
|
| 1.1 |
|
Underwriting Agreement, dated as of March 17, 2026, among CytomX Therapeutics, Inc. and Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein. |
|
|
| 4.1 |
|
Form of Pre-Funded Warrant. |
|
|
| 5.1 |
|
Opinion of Latham & Watkins LLP. |
|
|
| 23.1 |
|
Consent of Latham & Watkins LLP (included in Exhibit 5.1). |
|
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
